Clinical Trials in 2026: How the Next Generation of Research The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York An FDA Reversal on Peptides Could Open the Market to Unsafe Drugs ProPublica Clinical Research in 2026:What's Changing and Why It Matters